Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Auditor change
Acq. announced
Appointed director
Quarterly results
Consulting agrmnt

Ardea Biosciences, Inc. (RDEA) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/22/2012 8-K Quarterly results
06/13/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Proxy Statement Supplement"
06/05/2012 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection with Proposed Merger"
05/30/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ardea Biosciences Earns Milestone from Bayer HealthCare"
04/24/2012 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Ardea Biosciences, Inc., Zeneca Inc., and QAM Corp",
"Form of Voting Agreement, by and between Zeneca Inc. and certain directors and executive officers of Ardea Biosciences, Inc",
"ASTRAZENECA TO ACQUIRE ARDEA BIOSCIENCES FOR $1.26 BILLION INCLUDING LEAD PRODUCT LESINURAD IN PHASE III DEVELOPMENT FOR GOUT"
04/02/2012 8-K Form 8-K - Current report
03/09/2012 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results SAN DIEGO, March 9, 2012 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and announced fourth quarter and full-year 2011 financial results. “The proceeds of $157.6 million from our recent financing, added to our existing cash balance, put us in an excellent financial position,” commented Barry D. Quart, PharmD, Ardea's president and chief executive officer. “We believe these resources should fund operations beyond the estimated primary endpoint dates of all four of the planned Phase 3 studies of lesinurad that are now fully underway.” Recen..."
01/31/2012 8-K Results of Operations and Financial Condition, Other Events
01/09/2012 8-K Form 8-K - Current report
12/22/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/19/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad"
11/07/2011 8-K Form 8-K - Current report
11/04/2011 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Ardea Biosciences Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results SAN DIEGO, November 4, 2011 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the three and nine months ended September 30, 2011. “Since our last quarterly update, we have advanced our development program for lesinurad and continue to target commencing Phase 3 studies before the end of this year,” commented Barry D. Quart, PharmD, president and chief executive officer. “We completed formal End-of-Phase 2 meetings with the FDA and received clear feedback and reached agreement on key aspects of our proposed Phase 3 p..."
09/07/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad",
"Ardea Biosciences, Inc. presentation materials and to be used from time to time thereafter"
08/05/2011 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results SAN DIEGO, August 5, 2011 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2011. “Since our last quarterly update, we presented exciting initial results from the ongoing extension portion of our Phase 2b trial of lesinurad demonstrating high rates of sustained uric acid lowering and patient response over week 28 of the study at all doses,” commented Barry D. Quart, PharmD, president and chief executive officer. “These results, together with the impressive efficacy and safety profile establis..."
05/25/2011 8-K Form 8-K - Current report
05/09/2011 8-K Quarterly results
Docs: "Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results SAN DIEGO, May 9, 2011 — Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2011. “Results from our recently completed Phase 2b study of lesinurad in combination with allopurinol demonstrate lesinurad's potential to bring relief to millions of patients currently suffering with gout,” commented Barry D. Quart, PharmD, Ardea's president and chief executive officer. “We look forward to presenting additional results from this study at the Annual European Congress of Rheumatology in May and discussing our ..."
04/08/2011 8-K Form 8-K - Current report
03/11/2011 8-K Form 8-K - Current report
01/21/2011 8-K Form 8-K - Current report
01/19/2011 8-K Form 8-K - Current report
01/10/2011 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration"
01/06/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients",
"Ardea Biosciences, Inc. presentation materials, and to be used from time to time thereafter"
11/18/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Poster on BAY 86-9766 (formerly known as RDEA119) presented at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” in Berlin, Germany"
11/09/2010 8-K Form 8-K - Current report
11/08/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ardea Biosciences Announces Positive Results for RDEA594 in Combination with Febuxostat or Allopurinol in Gout Patients",
"Ardea Biosciences, Inc. presentation materials date as of November 8, 2010, and to be used from time to time thereafter"
10/22/2010 8-K/A Form 8-K - Current report [amend]
10/07/2010 8-K Form 8-K - Current report
09/17/2010 8-K Form 8-K - Current report
08/06/2010 8-K Form 8-K - Current report
06/18/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology",
"Ardea Biosciences, Inc. presentation materials, and to be used from time to time thereafter"
05/27/2010 8-K Submission of Matters to a Vote of Security Holders
05/10/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Ardea Biosciences, Inc. presentation materials, and to be used from time to time thereafter"
05/07/2010 8-K Quarterly results
Docs: "Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2010 Financial Results SAN DIEGO, May 7, 2010 — Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus , today reported recent accomplishments and financial results for the first quarter ended March 31, 2010. “We are pleased to have accomplished a number of very important objectives since our last quarterly update,” commented Barry D. Quart, PharmD, president and chief executive officer of Ardea. “In March, we announced positive, preliminary top-line results from our completed Phase 2b monotherapy study of RDEA594 and, shortly thereafter, we were able to significantly strengthen our financial posit..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy